Aflibercept
![FDA to Approve Eylea’s Breakthrough Dose for Diabetic Eye Disease](https://pharmtales.com/wp-content/uploads/2023/08/Regenerons-High-Dose-Eylea-Demonstrates-Persistence-as-FDA-Decision-Looms.jpg)
Regeneron’s High-Dose Eylea Demonstrates Persistence as FDA Decision Looms
SG Tylor
While awaiting an FDA decision regarding a higher-dose version of Eylea (aflibercept), Regeneron has consistently emphasized the durability of their ...